Risteys ·

OMOP concept ID	Test name	Measurement unit (harmonized unit)	N people	N records	Missing measurement value	Harmonized value distribution	Test outcome NA N A AA L LL H HH
3011436	s-histab	— (—)	926	1006	100.00%	Distribution not available
3011436	s-histab	U/ml (u/ml)	29	35	42.86%

LabWAS

N Cases

N Controls

-log₁₀(p)

cases

controls

cases

controls

unit

-log₁₀(p)

N cases

N controls

Autoimmune diseases related-to ILD

354

523

5.68

176.53

1.1

29.78

9.83

u/ml

—

Respiratory diseases principally affecting the interstitium, IBD co-morbidites

30.55

79.76

1.0

—

u/ml

—

Other disorders of skin and subcutaneous tissue

205

593

2.93

42.62

1.1

21.40

30.00

u/ml

—

ILD, hospital admission 2, with pulmonary infections

7.25

34.73

1.1

1.0

—

u/ml

—

Fibromyalgia

7.11

28.80

1.1

1.0

—

Asthma, excluding more controls

155

268

2.97

28.69

1.1

—

5.43

u/ml

—

Asthma

159

285

2.88

27.99

1.1

—

5.43

u/ml

—

Asthma (only as main-diagnosis), excluding more controls

140

268

2.89

25.47

1.1

—

5.43

u/ml

—

Asthma (mode)

153

290

2.78

25.46

1.1

—

5.43

u/ml

—

Asthma (only as main-diagnosis)

144

285

2.83

25.31

1.0

1.1

—

5.43

u/ml

—

Asthma, unspecified (mode), excluding more controls

112

257

3.12

25.14

1.1

—

6.60

u/ml

—

Asthma, unspecified (mode)

113

273

2.99

23.71

1.1

—

6.60

u/ml

—

Examination and observation for other reasons

113

218

2.93

21.24

1.1

—

6.00

—

Other peripheral vascular diseases

5.74

20.22

1.1

1.0

—

u/ml

—

COPD/asthma/ILD related infections

207

483

2.15

20.15

1.1

31.33

5.67

u/ml

—

COPD/asthma related infections

207

483

2.15

20.15

1.1

31.33

5.67

u/ml

—

Disorders of thyroid, IBD co-morbidities

8.18

19.56

1.1

1.0

—

Sciatica+with lumbago

118

428

2.45

17.87

1.1

—

27.86

u/ml

—

Other necrotizing vasculopathies

5.88

15.71

1.1

—

Gastro-oesophageal reflux disease

145

580

2.11

15.49

1.1

—

27.50

u/ml

—

Other disorders of lacrimal gland

379

2.43

14.25

1.1

—

39.67

u/ml

—

217

600

1.83

13.94

1.1

41.00

13.00

u/ml

—

Myalgia

196

3.02

13.87

1.2

1.1

—

48.60

—

Asthma (diagnoses ohter than nonallergic)

176

753

1.89

13.74

1.1

—

24.77

u/ml

—

Disorders of lacrimal system

105

465

2.23

13.25

1.1

—

36.71

u/ml

—

Asthma-related infections

122

581

2.05

12.49

1.1

—

26.50

u/ml

—

Asthma, hospital admission 2, infections

122

581

2.05

12.49

1.1

—

26.50

u/ml

—

Disturbances of skin sensation

253

2.62

11.95

1.0

1.1

—

33.80

u/ml

—

Bronchitis

208

716

1.74

11.88

1.1

38.20

13.60

u/ml

—

Lumbar disc prolapse

121

446

2.01

11.23

1.1

—

27.86

—

Gout

132

3.06

10.99

1.1

1.0

—

u/ml

—

All kidney diseases

187

721

1.74

10.87

1.1

—

23.14

u/ml

—

Viral infections characterized by skin and mucous membrane lesions, including avohilmo

174

770

1.76

10.87

1.1

45.40

10.00

u/ml

—

Nutritional anaemias

102

470

2.07

10.78

1.1

—

36.71

u/ml

—

All chronic kidney diseases

108

420

2.05

10.77

1.0

1.1

—

21.20

u/ml

—

Other intervertebral disc disorders

145

462

1.87

10.48

1.1

—

27.86

—

Bacterial infection, other or unspecified, including avohilmo

111

455

2.00

10.40

1.1

—

21.20

—

Juvenile rheumatoid arthirtis

23.66

10.26

1.1

1.0

—

429

2.11

10.16

1.1

—

27.70

u/ml

—

Complications of surgical and medical care, not elsewhere classified

186

728

1.71

10.14

1.1

—

27.73

u/ml

—

Osteoporosis with pathological fracture (FG)

5.03

10.04

1.1

1.0

—

Carpal tunnel syndrome

120

549

1.90

9.76

1.1

—

35.00

u/ml

—

Certolizumab pegol

13.59

9.70

1.3

1.2

—

u/ml

—

Iron deficiency anaemia

414

2.09

9.60

1.1

—

21.20

u/ml

—

Renal tubulo-interstitial diseases

162

690

1.72

9.34

1.1

—

24.77

u/ml

—

Asthma, hospital admissions , main diagnosis only

153

768

1.73

9.33

1.1

—

24.77

u/ml

—

Obesity related asthma

336

2.21

9.33

1.1

—

21.20

u/ml

—

Other CVD (FINNGEN)

3.76

8.97

1.1

—

Other/unspecified dorsalgia

330

2.16

8.61

1.1

—

37.60

u/ml

—

Vasomotor and allergic rhinitis

344

2.11

8.31

1.0

1.1

—

24.50

—

Complications of medical and surgical care

137

719

1.71

8.13

1.1

—

30.30

u/ml

—

Vocal cord dysfunction

4.13

8.05

1.0

1.1

—

u/ml

—

Abnormal results of function studies

3.85

7.96

1.1

—

Benign neoplasm: Colon

101

512

1.85

7.87

1.0

1.1

—

21.20

u/ml

—

Alopecia areata

9.48

7.79

1.1

—

u/ml

—

Follow-up examination after treatment for conditions other than malignant neoplasms

186

2.26

7.77

1.1

—

6.80

—

Dermatitis due to substances taken internally

6.97

7.76

1.3

1.0

—

u/ml

—

Other hammer toe(s) (acquired)

100

3.01

7.70

1.1

1.0

—

Atopic dermatitis, strict definition with reimbursement

206

2.38

7.69

1.1

—

8.63

u/ml

—

Asthma-related pneumonia

330

2.09

7.64

1.1

—

21.20

—

Asthma, hospital admissions 3, pneumonia

330

2.09

7.64

1.1

—

21.20

—

Asthma-related pneumonia or sepsis

330

2.09

7.64

1.1

—

21.20

—

Antihypertensive medication - note that there are other indications

248

1.96

7.58

1.1

31.00

8.50

u/ml

—

Cardiovascular diseases

260

1.94

7.55

1.1

32.80

11.50

u/ml

—

Gonarthrosis,primary

155

569

1.64

7.37

1.1

—

21.00

—

Complications of procedures, not elsewhere classified

145

709

1.65

7.36

1.1

—

30.30

u/ml

—

Other and unspecified iron deficiency

316

2.09

7.33

1.1

—

21.20

u/ml

—

Asthma, including avohilmo

202

720

1.55

7.31

1.1

—

21.80

u/ml

—

Erythema multiforme

10.97

7.31

1.2

—

u/ml

—

Heart failure and antihypertensive medication

110

2.54

6.82

1.1

—

Osteopathies and chondropathies

103

537

1.75

6.75

1.1

—

36.00

u/ml

—

Symptoms and signs involving the digestive system and abdomen

156

485

1.61

6.66

1.1

—

23.00

u/ml

—

Intracranial trauma

320

1.86

6.59

1.1

—

28.40

u/ml

—

Morphin

12.34

6.59

1.0

—

Chronic sinusitis

406

1.90

6.59

1.1

—

35.13

—

Polyarthritis, unspecified

8.73

6.55

1.2

1.0

—

u/ml

—

Benign neoplasm of colon, rectum, anus and anal canal

111

555

1.69

6.34

1.0

1.1

—

22.83

u/ml

—

Allergic rhinitis

273

2.06

6.21

1.0

1.1

—

26.29

—

Cardiovascular diseases (excluding rheumatic etc)

312

1.78

6.13

1.1

32.80

14.17

u/ml

—

Hypothyroidism, other/unspecified

150

630

1.57

6.06

1.1

—

18.75

u/ml

—

Abdominal and pelvic pain

152

485

1.57

5.94

1.1

—

23.00

u/ml

—

Migraine

410

1.75

5.85

1.1

—

26.27

u/ml

—

Nausea and vomiting

228

2.10

5.60

1.1

—

34.43

u/ml

—

Surgical operation and other surgical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure

100

602

1.66

5.50

1.1

—

30.30

u/ml

—

Drug-induced systemic lupus erythematosus

11.62

5.33

1.9

1.3

—

Hernia

155

686

1.50

5.26

1.1

—

27.73

u/ml

—

Concussion

315

1.80

5.16

1.1

—

28.40

u/ml

—

Dermatopolymyositis (FG)

13.50

5.09

1.0

—

u/ml

—

Irritable bowel syndrome

264

1.97

5.09

1.1

—

36.71

u/ml

—

Drug-induced osteoporosis with pathological fracture

10.13

5.04

1.2

—

Surgical and other medical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure

104

637

1.60

5.02

1.1

—

30.30

u/ml

—

Disorders of the thyroid gland

150

658

1.48

4.76

1.1

—

18.75

u/ml

—

Other headache syndromes

423

1.72

4.68

1.0

1.1

—

31.33

u/ml

—

Artificial joint operation, meniscal resection

144

620

1.49

4.67

1.1

—

18.63

—

Other and unspecified tonsillitis

233

1.89

4.50

1.1

—

5.83

u/ml

—

Disorders of other endocrine glands

439

1.68

4.44

1.1

—

30.75

u/ml

—

Other nutritional deficiencies

114

685

1.52

4.40

1.1

—

23.21

u/ml

—

Other specified/unspecified necrotizing vasculopathies

9.00

4.29

1.0

1.2

—

Dermatopolymyositis

9.00

4.29

1.0

1.2

—

u/ml

—

Crystal arthropathies, rheuma endpoint

8.97

4.28

1.0

—

Ischaemic heart disease, wide definition

119

486

1.51

4.16

1.1

—

19.86

u/ml

—

Other crystal arthropathies

8.07

4.07

1.0

—

Prurigo nodularis

8.06

4.06

1.4

1.1

—

Later onset COPD, excluding more controls

2.48

4.05

1.0

1.1

—

Premenstrual syndrome

10.09

4.02

1.1

—

u/ml

—

Bruxism

5.61

3.98

1.0

1.1

—

Any operation in hilmo

+∞

3.93

1.2

0.0

—

Gonarthrosis, primary, with knee surgery

448

1.56

3.90

1.1

—

22.83

—

Migraine with aura

226

1.90

3.89

1.1

—

28.67

u/ml

—

Migraine with aura and triptan purchases

151

2.12

3.88

1.1

—

32.60

u/ml

—

Psoriasis (vulgaris), strict definition

4.81

3.87

1.4

1.0

—

u/ml

—

Lung cancer and mesothelioma

2.40

3.74

1.0

1.1

—

Seronegative juvenile rheumatoid arthritis

6.72

3.68

1.1

1.2

—

u/ml

—

Obesity and other hyperalimentation

105

668

1.48

3.63

1.1

—

27.91

u/ml

—

Coxarthrosis, primary

515

1.52

3.61

1.1

—

22.83

—

Primary gonarthrosis, bilateral

427

1.57

3.59

1.1

—

22.83

—

Pyogenic arthritis

3.73

3.59

1.1

1.0

—

Acute tubulo-interstitial nephritis

560

1.49

3.55

1.1

—

27.70

u/ml

—

Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified

147

666

1.39

3.52

1.1

—

28.60

u/ml

—

Obesity

104

666

1.47

3.52

1.1

—

27.91

u/ml

—

Migraine without aura

171

1.99

3.52

1.1

—

28.67

u/ml

—

Chronic apical periodontitis

173

714

1.36

3.46

1.0

1.1

37.17

11.56

u/ml

—

Hypertensive Renal Disease

3.95

3.29

1.0

—

Pulmonary eosinophilia, not elsewhere classified

8.67

3.27

1.2

1.1

—

STROKE

355

1.54

3.23

1.1

—

11.80

u/ml

—

Other symptoms and signs involving the circulatory and respiratory systems

2.86

3.19

1.4

1.1

—

Type 2 diabetes, strict (exclude DM1)

149

636

1.36

3.11

1.1

—

23.60

u/ml

—

Retained placenta and membranes, without haemorrhage

2.23

3.05

1.2

1.1

—

Erythema nodosum

5.03

3.05

1.0

1.1

—

Temporal arteritis

4.31

2.99

1.2

1.0

—

Microscopic polyangiitis

10.19

2.99

1.4

1.2

—

Urticaria due to cold and heat

10.12

2.99

1.0

1.4

—

Other and unspecified pemphigoid

10.12

2.99

1.6

1.2

—

Type 2 diabetes, definitions combined

147

633

1.35

2.93

1.1

—

23.60

—

Pollen allergy

154

1.92

2.87

1.0

1.1

—

28.67

—

Unspecified urinary incontinence

2.25

2.86

1.1

1.0

—

All anxiety disorders

516

1.43

2.78

1.1

—

28.33

u/ml

—

Anxiety (asthma-related co-morbidities)

507

1.42

2.73

1.1

—

15.50

u/ml

—

Caries of enamel

147

724

1.33

2.70

1.2

1.1

10.67

36.57

u/ml

—

Erythema intertrigo

6.03

2.70

1.0

1.1

—

Type 2 diabetes

150

655

1.33

2.67

1.1

—

23.60

—

Obesity due to excess calories

527

1.46

2.65

1.1

—

30.30

u/ml

—

Postmenopausal osteoporosis with pathological fracture

2.55

2.61

1.1

—

Hyperhidrosis

4.68

2.60

1.0

1.1

—

Atopic dermatitis, strict definition

269

1.64

2.55

1.1

—

21.44

u/ml

—

Wegener granulomatosis

7.19

2.55

1.0

1.3

—

Secondary hypertension

2.69

2.47

1.0

1.2

—

Other neurological diseases

105

594

1.37

2.47

1.1

—

36.71

u/ml

—

Other and unspecified disease of Bartholin gland

3.83

2.46

1.0

1.1

—

Sodium-glucose co-transporter 2 (SGLT2) inhibitors

319

1.57

2.42

1.0

1.1

—

21.20

—

Glucagon-like peptide-1 (GLP-1) analogues

319

1.57

2.42

1.0

1.1

—

21.20

—

Causalgia

6.29

2.37

1.2

1.1

—

Varicose veins

493

1.39

2.37

1.1

—

21.00

u/ml

—

Diabetes, varying definitions

151

675

1.30

2.35

1.1

—

23.60

—

Giant cell arteritis

3.23

2.31

1.2

1.1

—

Special screening examination for infectious and parasitic diseases

106

1.86

2.27

1.1

—

6.80

—

Other disorders of urethra and urinary system

106

546

1.35

2.27

1.0

1.1

—

28.90

u/ml

—

Diabetes mellitus

151

677

1.29

2.25

1.1

—

23.60

—

Autoimmune hyperthyroidism

3.11

2.22

1.1

1.0

—

Eosinophilic disease (BM)

5.59

2.21

1.0

1.2

—

Tonsillectomy and adenotomy

384

1.41

2.20

1.2

1.1

—

21.80

u/ml

—

Migraine without aura and triptan purchases

151

1.79

2.15

1.1

—

32.60

u/ml

—

Diseases of pulp and periapical tissues, including avohilmo

150

605

1.28

2.13

1.1

44.00

10.63

u/ml

—

Nonsuppurative otitis media, including avohilmo

243

1.57

2.11

1.1

—

8.00

u/ml

—

Autoimmune thyroiditis

5.02

2.07

1.0

1.1

—

Other disorders of veins

441

1.43

2.03

1.1

—

34.88

u/ml

—

Outcome of delivery

0.34

1.95

1.0

1.2

—

7.80

—

Oligomenorrhoea

3.19

1.88

1.3

1.0

—

Dipeptidyl peptidase 4 (DPP-4) inhibitors

442

1.37

1.86

1.0

1.1

—

21.20

—

Type 2 diabetes, definitions combined, including avohilmo

139

636

1.26

1.84

1.1

—

23.60

—

Venous thromboembolism

531

1.36

1.82

1.1

—

21.20

u/ml

—

Intracranial injury

570

1.34

1.81

1.1

—

8.14

u/ml

—

Scabies, including avohilmo

116

1.81

1.78

1.2

1.1

—

8.00

—

Viral and other specified intestinal infections, including avohilmo

238

1.54

1.76

1.1

—

25.43

u/ml

—

Cardiac arrest

2.55

1.74

1.0

1.1

—

Malignant neoplasm of cervix uteri

3.87

1.71

1.2

1.1

—

Acute posthaemorrhagic anaemia

3.17

1.66

1.0

1.1

—

Other deformities of toe(s)

3.17

1.66

1.0

—

Other specified/unspecified soft tissue disorders

2.59

1.66

1.0

—

Other (not insulin) diabetes medications

143

677

1.24

1.65

1.1

—

27.73

u/ml

—

Medical abortion

413

1.30

1.64

1.0

1.1

—

27.40

u/ml

—

Perineal laceration during delivery

152

0.48

1.63

1.0

1.1

—

32.60

—

Benign neoplasm: Other/unspecified site

3.59

1.62

1.2

1.1

—

Anaemia in chronic diseases classified elsewhere

3.58

1.61

1.2

1.1

—

Malignant neoplasm of cervix uteri, including Hilmo

3.01

1.58

1.2

1.1

—

Female infertility, associated with anovulation

2.11

1.55

1.1

—

Obstructed labour due to malposition and malpresentation of fetus

207

1.52

1.53

1.0

1.1

—

31.33

u/ml

—

Injuries to the thorax

432

1.37

1.52

1.1

—

21.20

—

Injuries to the shoulder and upper arm

119

737

1.25

1.52

1.1

—

24.62

u/ml

—

Unspecified fall

509

1.33

1.51

1.0

1.1

—

17.50

u/ml

—

Open bite

2.44

1.48

1.0

1.1

—

Hernia of abdominal wall

444

1.35

1.47

1.1

—

43.80

u/ml

—

Diabetes medication

149

716

1.22

1.47

1.1

—

27.73

u/ml

—

Pustulosis palmaris et plantaris

2.51

1.45

1.0

—

Respiratory insufficiency

2.36

1.45

1.0

1.1

—

Other facial nerve disorders

3.13

1.44

1.0

1.1

—

Lichen simplex chronicus

3.13

1.44

1.4

1.1

—

Bronchiectasis

1.97

1.43

1.1

1.0

—

Abnormal findings on diagnostic imaging of central nervous system

2.42

1.39

1.1

—

Perioral dermatitis

2.95

1.36

1.0

1.1

—

Algoneurodystrophy

2.51

1.30

1.2

1.1

—

Pregnancy examination and test

1.62

1.28

1.0

1.2

—

7.00

u/ml

—

Obesity, other/unspecified

363

1.35

1.24

1.0

1.1

—

25.38

—

Exclusions for E4_PCOS_CONSORTIUM

106

538

1.23

1.1

—

22.64

u/ml

—

Emphysema

2.04

1.22

1.0

1.1

—

Unspecified chronic bronchitis

2.64

1.21

1.0

1.1

—

Lyme disease

348

1.35

1.20

1.1

—

21.20

—

Lyme disease, including avohilmo

348

1.35

1.20

1.1

—

21.20

—

Spirochaetal infections, other/unspecified, including avohilmo

348

1.35

1.20

1.1

—

21.20

—

Other spirochaetal diseases

349

1.35

1.18

1.1

—

21.20

—

Complications predominantly related to the puerperium

273

1.39

1.16

1.1

—

35.60

—

Other spirochaetal diseases, including avohilmo

350

1.34

1.16

1.1

—

21.20

—

Nonsuppurative otitis media

168

1.45

1.05

1.2

1.1

—

8.00

u/ml

—

All dysplastic lesions of the vagina

2.18

0.98

1.2

1.1

—

Other medical care

422

1.25

0.96

1.0

1.1

—

21.20

u/ml

—

Cyst of Bartholin Gland

2.23

0.93

1.0

1.1

—

Type 2 diabetes, wide definition

101

535

1.19

0.91

1.1

—

11.43

u/ml

—

Female infertility, tubal origin

2.07

0.89

1.2

1.1

—

Other sexually transmitted chlamydial diseases

1.82

0.85

1.1

—

Pediculosis, acariasis and other infestations, including avohilmo

153

1.44

0.85

1.3

1.1

—

8.00

—

Haemorrhage in early pregnancy

299

1.30

0.85

1.1

—

36.60

u/ml

—

Infections of breast associated with childbirth

1.88

0.82

1.0

1.1

—

Myocarditis

1.88

0.81

1.3

1.2

—

u/ml

—

Infections with a predominantly sexual mode of transmission

284

1.30

0.80

1.1

—

25.29

u/ml

—

Prolapse and hernia of ovary and fallopian tube

0.00

0.79

0.0

1.0

—

Personality disorders

243

1.32

0.76

1.1

—

23.63

u/ml

—

Biguanides

128

677

1.14

0.73

1.1

—

27.73

u/ml

—

Diabetes, insuline treatment (Kela reimbursement), excluding more controls

121

627

1.14

0.72

1.1

—

23.60

—

Other obstructed labour

1.60

0.68

1.2

1.1

—

Malignant neoplasm of corpus uteri, including Hilmo

0.54

0.66

1.0

1.1

—

Disorders of ocular muscles, binocular movement, accommodation and refraction

507

1.19

0.66

1.1

—

20.18

u/ml

—

Pregnancy with abortive outcome

418

1.16

0.66

1.1

—

27.40

u/ml

—

Disorders of vitreous body and globe

539

1.18

0.62

1.1

—

22.83

—

Wide developmental disorders

0.00

0.60

0.0

1.2

—

Amenorrhoea

1.57

0.60

1.3

1.1

—

Other predominantly sexually transmitted diseases, not elsewhere classified

157

1.34

0.59

1.1

—

33.80

u/ml

—

Diabetic nephropathy

138

1.36

0.58

1.1

—

Multiple delivery

1.50

0.54

1.1

—

1.58

0.54

1.0

1.1

—

Leiomyoma of uterus

434

1.14

0.52

1.1

—

39.00

u/ml

—

Labour and delivery complicated by fetal stress [distress]

156

1.25

0.51

1.2

—

28.83

—

Disorders of refraction and accommodation

259

1.23

0.50

1.1

—

8.00

u/ml

—

Exposure to other specified factors

104

799

1.12

0.50

1.0

1.1

—

23.14

—

Disorders of vitreous body

529

1.15

0.49

1.1

—

22.83

—

Insulin, combination of fast acting with intermediate-acting or long-acting

547

1.14

0.49

1.1

—

39.67

u/ml

—

Carcinoma in situ of breast, intraductal

0.59

0.45

1.4

1.1

—

Diabetes, insulin treatment (Kela reimbursement)

128

694

1.10

0.44

1.1

—

27.73

—

Other abnormal products of conception

227

1.19

0.44

1.2

1.1

—

31.00

—

Injuries to the hip and thigh

446

1.15

0.43

1.1

—

21.20

—

Placenta praevia

1.61

0.43

1.2

—

Insulin medication

507

1.13

0.42

1.1

—

36.71

u/ml

—

Other and unspecified disorders of vitreous body

452

1.15

0.41

1.1

—

22.83

—

Other diseases caused by chlamydiae, including avohilmo

0.00

0.41

0.0

1.1

—

Other disorders of breast and lactation associated with childbirth

0.00

0.41

0.0

1.1

—

Autism spe, excluding more controls

0.00

0.41

0.0

1.1

—

Malignant neoplasm of other and unspecified female genital organs

0.00

0.41

0.0

1.1

—

Assault by unspecified means

0.00

0.41

0.0

1.1

—

Other noninflammatory disorders of vagina

1.36

0.41

1.1

—

Autism spe

0.00

0.40

0.0

1.1

—

Autism

0.00

0.40

0.0

1.1

—

Wide developmental disorders, excluding more controls

0.00

0.40

0.0

1.1

—

Enterobiasis, including avohilmo

0.00

0.40

0.0

1.2

—

Mental and behavioural disorders due to use of other stimulants, including caffeine

0.00

0.39

0.0

1.1

—

Postpartum hemorraghe, all women as controls

254

1.19

0.38

1.1

—

27.29

—

Pure hypercholesterolaemia

511

1.11

0.38

1.1

—

13.20

—

Postpartum haemorrhage

216

1.18

0.36

1.1

—

27.43

—

Disorders of adult personality and behaviour

263

1.18

0.35

1.1

—

23.63

u/ml

—

Dislocation, sprain and strain of joints and ligaments of knee

632

0.90

0.33

1.1

—

23.14

—

Labour and delivery complicated by umbilical cord complications

1.28

0.32

1.0

1.1

—

Procreative management

251

1.15

0.30

1.0

1.1

—

7.13

u/ml

—

Antenatal screening

122

0.83

0.28

1.0

1.2

—

7.00

u/ml

—

Persons encountering health services in circumstances related to reproduction

399

0.91

0.26

1.0

1.1

—

6.56

u/ml

—

Postpartum hemorraghe, parous women as controls

227

1.14

0.26

1.1

—

26.29

—

Care involving use of rehabilitation procedures

624

1.08

0.24

1.1

—

26.27

u/ml

—

Specific personality disorders

208

1.15

0.24

1.0

1.1

—

8.00

u/ml

—

Tooth eruption problems

120

1.21

0.23

1.3

1.1

—

8.67

u/ml

—

Other disorders of eyelid

432

1.09

0.21

1.1

—

21.20

—

Respiratory and cardiovascular disorders specific to the perinatal period

0.00

0.21

0.0

1.2

—

Other and unspecified disorders of psychological development

0.00

0.21

0.0

1.1

—

Caries in Clefts patients

0.00

0.21

0.0

1.2

—

Other diseases caused by chlamydiae

0.00

0.21

0.0

1.2

—

Carcinoma in situ of cervix uteri, endocervix

0.00

0.21

0.0

1.2

—

Benign neoplasm: Tonsil

0.00

0.21

0.0

1.1

—

Carcinoma in situ of breast, other/unspecified

0.00

0.21

0.0

1.1

—

Deep bite that required surgery

0.00

0.21

0.0

1.2

—

Poisoning by medicine, drug-induced

0.00

0.21

0.0

1.2

—

Conotruncal defects

0.00

0.21

0.0

1.2

—

Intentional self-harm by unspecified means

0.00

0.21

0.0

1.2

—

Hydatidiform mole

0.00

0.21

0.0

1.1

—

Use of cabergoline

0.00

0.21

0.0

1.1

—

Cleft lip, lip and palate or palate

0.00

0.21

0.0

1.2

—

Behavioural disorders, excluding more controls

0.00

0.21

0.0

1.1

—

Human immunodeficiency virus [HIV] disease resulting in other conditions

0.00

0.21

0.0

1.2

—

Human immunodeficiency virus [HIV] disease resulting in other conditions, including avohilmo

0.00

0.21

0.0

1.2

—

Disorders in reading

0.00

0.21

0.0

1.1

—

Human immunodeficiency virus [HIV] disease

0.00

0.21

0.0

1.2

—

Human immunodeficiency virus [HIV] disease, including avohilmo

0.00

0.21

0.0

1.2

—

Abnormal findings in nipple discharge synovial fluid wound secretions

0.00

0.21

0.0

1.2

—

Diseases caused by chlamydiae, including avohilmo

0.00

0.21

0.0

1.2

—

Mandibular prognathia

0.00

0.21

0.0

1.2

—

Use of amantadine

0.00

0.21

0.0

1.2

—

Other and unspecified mental retardation

0.00

0.21

0.0

1.2

—

COPD-related respiratory insufficiency

1.23

0.21

1.0

—

Habit and impulse disorders

0.00

0.21

0.0

1.1

—

Benign neoplasm: Vulva

0.00

0.21

0.0

1.2

—

Behavioural disorders

0.00

0.21

0.0

1.2

—

Conduct disorder

0.00

0.21

0.0

1.1

—

Mental and behavioural disorders due to cannabinoids

0.00

0.21

0.0

1.2

—

Carcinoma in situ of other and unspecified genital organs

0.00

0.20

0.0

1.1

—

Mouth breathing

374

1.09

0.19

1.0

1.1

—

11.20

u/ml

—

Peritonsillar abscess

165

1.15

0.19

1.0

1.1

—

34.20

—

Inflammatory disease of cervix uteri

1.19

0.18

1.0

1.1

—

Bronchitis, not specified as acute or chronic

1.13

0.17

1.1

1.0

—

Insulin, intermediate and long-acting

515

1.07

0.16

1.0

1.1

—

21.20

u/ml

—

Fracture of shoulder and upper arm

358

0.92

0.15

1.0

1.1

—

21.20

—

Otitis media, unspecified

1.18

0.12

1.3

1.1

—

9.80

—

Cerebrovascular diseases

545

1.04

0.11

1.1

—

21.20

u/ml

—

Diabetes mellitus in pregnancy

218

0.93

0.11

1.1

—

25.25

u/ml

—

Melanocytic naevi

321

0.93

0.10

1.0

1.1

—

31.33

—

Antepartum haemorrhage, not elsewhere classified

1.08

0.07

1.1

—

u/ml

—

Other noninflammatory disorders of vulva and perineum

1.07

0.07

1.0

1.1

—

Maternal care for other conditions predominantly related to pregnancy

211

1.06

0.06

1.1

—

31.00

u/ml

—

Injuries to the knee and lower leg

147

783

1.01

0.04

1.1

—

21.80

u/ml

—

In situ neoplasms

427

1.03

0.04

1.1

—

39.67

u/ml

—

Diabetic retinopathy, strict definition

134

1.06

0.03

1.1

—

Later onset COPD

208

0.96

0.02

1.0

1.1

—

Fracture of lower leg, including ankle

608

1.02

0.02

1.0

1.1

—

30.10

—

Other maternal disorders predominantly related to pregnancy

431

1.02

0.02

1.1

—

27.73

u/ml

—

Diabetic maculopathy

107

1.06

0.01

1.2

1.1

—

Superficial injury of lower leg

257

0.97

0.01

1.2

1.1

—

8.00

—

Adenomyosis (Endometriosis of uterus)

132

0.98

0.00

1.2

1.1

—

Long labour

206

0.99

0.00

1.0

1.1

—

31.33

u/ml

—

Erosion of teeth , including avohilmo

248

1.01

0.00

1.0

1.1

—

33.80

—

Diabetic neuropathy

1.02

0.00

1.0

1.1

—

Precocious central puberty

0.00

0.0

1.2

—

Metabolic disorder, other/unspecified

0.00

0.0

1.2

—

Early syphilis

0.00

0.0

1.2

—

Shigellosis, including avohilmo

0.00

0.0

1.3

—

Sequelae of transport accidents

0.00

0.0

1.3

—

Secondary sideroblastic anaemia

0.00

0.0

1.2

—

Congenital malformations of spine and bony thorax, including avohilmo

0.00

0.0

1.4

—

Melanocytic naevi of eyelid, including canthus

0.00

0.0

1.2

—

Acute disseminated encephalitis/encephalomyelitis

0.00

0.0

1.2

—

Other injuries of upper limb, level unspecified

0.00

0.0

1.3

—

Benign neoplasm: Vertebral column

0.00

0.0

1.2

—

Cervical root disorders

0.00

0.0

1.0

—

Carcinoma in situ of cervix uteri, exocervix

0.00

0.0

1.2

—

Thalassaemia

0.00

0.0

1.2

—

Measles

0.00

0.0

1.1

—

Other congenital malformations of female genitalia

0.00

0.0

1.2

—

Assault by other specified means

0.00

0.0

1.3

—

Delayed puberty

0.00

0.0

1.2

—

Drug-induced headache, not elsewhere classified

0.00

0.0

1.3

—

Other prurigo

0.00

0.0

1.2

—

Carcinoma in situ of vagina

0.00

0.0

1.3

—

Benign neoplasm: Bones of skull and face

0.00

0.0

1.2

—

Poisoning by and exposure to other and unspecified chemicals and noxious substances, undetermined intent

0.00

0.0

1.2

—

Injury of nerves and spinal cord at thorax level

0.00

0.0

1.3

—

Migraine, unspecified, drug-induced

0.00

0.0

1.1

—

Other and unspecified disorders of adult personality and behaviour

0.00

0.0

1.2

—

Clubfoot

0.00

0.0

1.3

—

Abnormal findings in cerebrospinal fluid

0.00

0.0

1.2

—

Erysipeloid, including avohilmo

0.00

0.0

1.2

—

Hereditary deficiency of other clotting factors

0.00

0.0

1.1

—

0.00

0.0

1.3

—

Congenital musculoskeletal deformities of head, face, spine and chest, including avohilmo

0.00

-0.00

0.0

1.2

—

Other specified transport accidents

0.00

-0.00

0.0

1.2

—

Lack of expected normal physiological development

0.00

-0.00

0.0

1.2

—

Mixed specific developmental disorders

0.00

-0.00

0.0

1.1

—

Vitamin A deficiency

0.00

-0.00

0.0

1.2

—

Burn and corrosion, body region unspecified

0.00

-0.00

0.0

1.2

—

Thyrotoxicosis with toxic single thyroid nodule

0.00

-0.00

0.0

1.2

—

Symptoms and signs involving appearance and behaviour

0.00

-0.00

0.0

1.3

—

Toxic effect of other noxious substances eaten as food

0.00

-0.00

0.0

1.0

—

Unattended death

0.00

-0.00

0.0

1.2

—

Injury of blood vessels at abdomen, lower back and pelvis level

0.00

-0.00

0.0

1.2

—

Vaginal lichen planus

0.00

-0.00

0.0

1.1

—

Exposure to excessive heat of man-made origin

0.00

-0.00

0.0

1.2

—

Toxic effect of other gases, fumes and vapours

0.00

-0.00

0.0

1.2

—

Bus occupant injured in other and unspecified transport accidents

0.00

-0.00

0.0

1.3

—

Fall involving playground equipment

0.00

-0.00

0.0

1.3

—

Contact with other specified venomous animals

0.00

-0.00

0.0

1.3

—

General- and plastic-surgery devices associated with adverse incidents

0.00

-0.00

0.0

1.4

—

Motor- or nonmotor-vehicle accident in traffic area

0.00

-0.00

0.0

1.2

—

Pedestrian injured in other and unspecified transport accidents

0.00

-0.00

0.0

1.3

—

Occupant of pick-up truck or van injured in other and unspecified transport accidents

0.00

-0.00

0.0

1.3

—

Other zoonotic bacterial diseases, not elsewhere classified, including avohilmo

0.00

-0.00

0.0

1.2

—

Sequelae of intentional self-harm, assault and events of undetermined intent

0.00

-0.00

0.0

1.3

—

Pedestrian injured in collision with two- or three-wheeled motor vehicle

0.00

-0.00

0.0

1.2

—

Defect, injury or illness of neck

0.00

-0.00

0.0

1.3

—

Right side

0.00

-0.00

0.0

1.2

—

Measles, including avohilmo

0.00

-0.00

0.0

1.1

—

Left side

0.00

-0.00

0.0

1.2

—

Hand

0.00

-0.00

0.0

1.2

—

Ankle and foot

0.00

-0.00

0.0

1.3

—

Personal history of allergy to analgesic agent

0.00

-0.00

0.0

1.1

—

Previous suicide attempt

0.00

-0.00

0.0

1.3

—

Acquired stenosis of external ear canal

0.00

-0.00

0.0

1.1

—

Social disorders starting during childhood or adolecense, excluding more controls

0.00

-0.00

0.0

1.2

—

Serous carcinoma of ovary

0.00

-0.00

0.0

1.0

—

Unspecified human immunodeficiency virus [HIV] disease

0.00

-0.00

0.0

1.3

—

Nonpyogenic thrombosis of intracranial venous system

0.00

-0.00

0.0

1.3

—

Severe combined immunodeficiency [SCID] with reticular dysgenesis

0.00

-0.00

0.0

1.2

—

Ovarian dysfunction, other/unspecified

0.00

-0.00

0.0

1.3

—

Personal history of allergy to drugs, medicaments and biological substances

0.00

-0.00

0.0

1.2

—

Right ventricular outflow tract obstruction

0.00

-0.00

0.0

1.4

—

Necrobiosis lipoidica, not elsewhere classified

0.00

-0.00

0.0

1.4

—

Acute mastoiditis

0.00

-0.00

0.0

1.2

—

Injury of nerves and lumbar spinal cord at abdomen, lower back and pelvis level

0.00

-0.00

0.0

1.4

—

Enteropathogenic Escherichia coli infection

0.00

-0.00

0.0

1.4

—

Acromegaly and pituitary gigantism

0.00

-0.00

0.0

1.2

—

Defect, injury or illness of lumbar spine

0.00

-0.00

0.0

1.2

—

Polyarteritis nodosa

0.00

-0.00

0.0

1.3

—

Histrionic personality disorder

0.00

-0.00

0.0

1.2

—

Other injuries of spine and trunk, level unspecified

0.00

-0.00

0.0

1.3

—

Rheumatic fever without mention of heart involvement

0.00

-0.00

0.0

1.2

—

Other and unspecified neuropathies

0.00

-0.00

0.0

1.2

—

Melanoma in situ of lower limb, including hip

0.00

-0.00

0.0

1.1

—

Other benign neoplasm of uterus: Cervix uteri

0.00

-0.00

0.0

1.2

—

Enterobiasis

0.00

-0.00

0.0

1.3

—

Apocrine sweat disorders, other sweat gland disorders

0.00

-0.00

0.0

1.2

—

Motor disorders

0.00

-0.00

0.0

1.3

—

Other congenital malformations of ear

0.00

-0.00

0.0

1.3

—

≡ Risteys

R14

FinnGen R13 + FinRegistry

FinnGen R12 + FinRegistry

FinnGen R11 + FinRegistry

FinnGen R10 + FinRegistry

FinnGen R10

FinnGen R9

FinnGen R8

FinnGen R7

FinnGen R6

FinnGen R5

FinnGen R4

FinnGen R3

Histone Ab [Units/volume] in Serum

Coding

Definition

OMOP mapping QC

Cohort

Year of birth distribution

Age at first measurement

Age at last measurement

Age at start of registry

Duration from first to last measurement

Statistics

Number of measurements over the years

Number of measurements per person

Distribution of lab values

Value range per person

LabWAS